Myriad Genetics, Inc. (MYGN) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $4.91. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is MYGN = $6 (+22.2% upside).
Valuation: MYGN trades at a trailing Price-to-Earnings (P/E) of -1.2 (S&P 500 average ~25).
Financials: revenue is $825M, +6.9%/yr average growth. Net income is $366M (loss), growing at -90.3%/yr. Net profit margin is -44.4% (negative). Gross margin is 69.9% (-0.3 pp trend).
Balance sheet: total debt is $210M against $368M equity (Debt-to-Equity (D/E) ratio 0.57, moderate). Current ratio is 2.49 (strong liquidity). Debt-to-assets is 29.7%. Total assets: $707M.
Analyst outlook: 8 / 36 analysts rate MYGN as buy (22%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 54/100 (Partial), Future 46/100 (Partial), Income 10/100 (Fail).
